Aberrant expression of CD30 in neoplastic mast cells in high-grade mastocytosis
- 1 April 2011
- journal article
- research article
- Published by Elsevier BV in Laboratory Investigation
- Vol. 24 (4), 585-595
- https://doi.org/10.1038/modpathol.2010.224
Abstract
No abstract availableKeywords
This publication has 48 references indexed in Scilit:
- Expression of Activated STAT5 in Neoplastic Mast Cells in Systemic Mastocytosis: Subcellular Distribution and Role of the Transforming Oncoprotein KIT D816VThe American Journal of Pathology, 2009
- Variable presence of KITD816V in clonal haematological non‐mast cell lineage diseases associated with systemic mastocytosis (SM–AHNMD)The Journal of Pathology, 2009
- Oncogenic Kit controls neoplastic mast cell growth through a Stat5/PI3-kinase signaling cascadeBlood, 2008
- CD30-Induced Signaling Is Absent in Hodgkin's Cells but Present in Anaplastic Large Cell Lymphoma CellsThe American Journal of Pathology, 2008
- Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patientsLeukemia, 2006
- Mast cells express functional CD30 ligand and are the predominant CD30L‐positive cells in Hodgkin's diseaseBritish Journal of Haematology, 2001
- CD30 in Normal and Neoplastic CellsClinical Immunology, 1999
- Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product.JCI Insight, 1993
- Production of a monoclonal antibody specific for Hodgkin and Sternberg–Reed cells of Hodgkin's disease and a subset of normal lymphoid cellsNature, 1982
- Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.Journal of Histochemistry & Cytochemistry, 1981